Publications

contact us

Get in contact with us via the contact form or email: info@aberabio.com

Abera Bioscience AB
Virdings allé 32
754 50 Uppsala
info@aberabio.com

Name

Phone number

Email

Message

Abera Bioscience is a Swedish biotechnology company developing next-generation nasal vaccines based on a modular OMV platform. Our pipeline includes a serotype-independent pneumococcal vaccine entering clinical development and a nasal influenza vaccine supported by international partners.

Abera Bioscience AB
Virdings allé 32
754 50 Uppsala
info@aberabio.com

Home
About Abera
Technology
Projects
News
Investors
Contact

Home
About Abera
Technology
Projects
News
Investors
Contact

Publications

contact us

NEws

Benefits of mucosal immunization: A New Paradigm in Vaccine Protection

Delårsrapport Q3 2025 Abera Bioscience AB

Artikel: Influensa och kampen mot framtida pandemier